36^th World Conference on Neurology July 18-19, 2024 Paris, France

Yingxu Wang is professor of cognitive informatics, brain science and denotational mathematics. He is President of International Institute of Cognitive Informatics and Cognitive Computing (ICIC). He is Fellows of BCS, ICIC, WIF, and Senior Members of IEEE and ACM. He has held visiting professor positions at Oxford University (’95), Stanford University (‘08|’16), UC Berkeley (‘08), and MIT (‘12). He is the initiator of fields of cognitive informatics, denotational mathematics, abstract intelligence (aI), neural circuit theory, formal brain models, cognitive robots and cognitive machine learning. He is a top 2.5% scholar worldwide and top 10 at UCalgary according to Research Gate’s statistics

Neuroinformatics, neurology, neural signaling systems, spike frequency modulation, SFM, cognitive informatics, mathematical models, neural networks, cognitive system, cognitive robots, brain-machine interface

Ronald J. Swatzyna is a distinguished neuroscientist and visionary leader in the field of neurology and neuropsychology. As the Director of Electro-Neuro Analysis Research, located in the United States, Dr. Swatzyna has made significant contributions to the understanding and treatment of neurological disorders, impacting the lives of countless individuals worldwide.

Neuroinformatics, neurology, neural signaling systems, spike frequency modulation, SFM, cognitive informatics, mathematical models, neural networks, cognitive system, cognitive robots, brain-machine interface

Dr. Dafin F. Muresanu is a highly accomplished neurologist and academician with a distinguished career in the field of neurology. He currently holds the position of Professor of Neurology and serves as the Senior Neurologist at the Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu" in Cluj-Napoca. In addition to his academic roles, he is also the Chairman of the Neurosciences Department at the same institution.

Neuroprotection, Neuroplasticity, Neuroregeneration

Ivan G. Milanov is a highly accomplished neurologist and healthcare leader from Bulgaria. He earned his MD in 1981, specializing in movement disorders, multiple sclerosis, headache, pain, and clinical electromyography. He's held prominent positions in academia and medical societies, including serving as the President of multiple Bulgarian neurological organizations. Dr. Milanov has also made significant contributions as an editor for various medical journals.

Rsearch Interest: movement disorders, multiple sclerosis, headache, pain, clinical electromyography

Dr Katz is a native New Yorker, born and bred here, and a product of its public schools. After graduating from the Bronx High School of Science, he attended Colgate University in Hamilton, NY, and graduated at the tender ago of 19, magna cum laude and Phi Beta Kappa. He was an Austen Colgate Scholar and thereafter went on to Case Western Reserve University School of Medicine in Cleveland, Ohio, where he graduated with Honors, and was given the Binz Scholar award for academic excellence. During his medical school years he served as an honorary registrar at the National Hospital for Nervous Diseases at Queen’s Square, London, England. Following medical school Dr. Katz went on to train in Internal Medicine at Parkland Hospital in Dallas, Texas. Thereafter he went to the National Institutes of Health in Bethesda, Maryland where he did research in Neuro-Virology. Following that, he completed a Neurology residency at Harvard Medical School, the Peter Bent Brigham Hospital, Boston Children’s Hospital and the Beth Israel Medical Center, all in Boston. Next he completed an Ophthalmology residency at the Tufts-New England Medical Center, again in Boston. Following that he went for fellowship to the University of California at San Francisco, in Neuro-Ophthalmology. Forced to find work, he joined the faculty of the University of Arizona and continued to pursue an academic career that brought him to the University of California at San Diego, UCSF and Pacific Medical Center in San Francisco, the University of Rochester in Rochester, NY, and the George Washington University in Washington, D.C., where he served as Chairman of the Department of Ophthalmology. While there he established the first FDA Fellowship in Ophthalmology Drug Development. Along the way he obtained an M.B.A. in Health Care and Finance form the University of Rochester’s School of Business. He moved to industry full time, and has been part of three starts up Ophthalmology Drug development companies. The first, Eyetech, in NYC, brought the first drug for macular degeneration to market. He then served as CMO of Fovea Pharmaceuticals in Paris, and next as CEO of Danube Pharmaceuticals, in NYC. All were successfully sold. He came back to academia and joined Roy Chuck M.D., Ph.D. at Albert Einstein College of Medicine and Montefiore Medical Center in NYC. There he has worked with Dr. Chuck to make that department one of the strongest in the Northeast. He serves as the Francis DeJur Chair of Ophthalmology, and is Professor of Ophthalmology, Neurology and Neurosurgery. In addition, he serves as Executive Director of the Office of Clinical Trials, which manages all trials in all arenas for the medical college and the hospital. He is a renowned teacher, educator and diagnostician, a much sought after consultant, and truly a doctor’s doctor. He is widely published with over 200 citations, has been an invited speaker and visiting professor at over 100 centers, has served on the editorial board of several major specialty journals, has been a funded research from both the NIH and industry. He has held active leadership positions in multiple organizations such as the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society. He has served on the board of several companies, delivered many named lectureships, and is still Chairman of the Board of both World Eye Missions and the Center for Ophthalmology Research and Education, both philanthropic ventures. He has led and done surgery in medical missions around the world from Bulgaria to Zimbabwe, from Guatemala to Peru, from Trinidad to St Lucia. He holds several patents in Ophthalmology drugs and technology. He is an avid fly fisherman, a mediocre golfer, a devoted sailor, and a frustrated country western musician on the 5 strings Banjo and 12-string guitar. He has been married to Deborah Ann for 35 years; together they have four children – Nathaniel, Sarah, Matthew and Jacob - five grand daughters and one grandson. They live and reside in Manhattan.

Reserach Interest: NEURO-Ophthalmology

Dr. Ye received his undergraduate training in Organic Chemistry at Jilin University, China (BS, 1990); Graduate training in Polymer Chemistry at Beijing University, China (MS, 1993); and Graduate training in Biochemistry at Emory University, Atlanta, Georgia, USA (Ph.D. 1998); Postdoctoral training with Dr. Solomon H. Snyder at Johns Hopkins University (1998-2001). At the end of 2001, he joined the faculty of Emory University School of Medicine (Assistant Professor in Department of Pathology and Laboratory Medicine, 2001-2007; Associate professor, 2007-2010; Full Professor, 2010-Present). Dr. Ye is the recipient of numerous professional honors, including the Distinguished Scientist Award from the Sontag Foundation (2003) and American Cancer Research Scholar (2004), and he is also one of the semi-finalists for Keck Foundation (2004). He has published approximately 140 papers with numerous papers in top journals including: Cell, Nature, Nature Medicine, Nature Cell Biology, Nature Neuroscience, Neuron, Mol. Cell, EMBO J, PNAS etc. Dr. Ye has made a unique contribution to the anti-cancer drug arsenal in 1998, when he was a graduate student at Emory. He discovered a novel opium alkaloid, noscapine, as an anti-cancer drug. He has shown that noscapine binds to tubulin, affects microtubule assembly, and arrests mammalian cells in mitosis. Furthermore, noscapine causes apoptosis and has potent antitumor activity. His discovery was broadly reported by numerous major media including ABC News, CNN and Science Magazine in 1998. He has several patents on this drug. In 2000, Dr. Ye disclosed a long-awaited nuclear GTPase, PIKE, which specifically regulates nuclear PI 3-kinase signaling cascade. This finding provides insight into the molecular mechanism of how nuclear PI 3-kinase is activated in the nucleus. Moreover, he found that PLC-1 acts as a guanine nucleotide exchange factor (GEF) for PIKE GTPase. In 2001, he was nominated as an assistant professor at Emory University. In 2003, he found that PIKE-L isoform can mediate mGluR’s anti-apoptotic action by binding to its adaptor protein Homer. This finding indicates that the PIKE-L/Homer complex mediates the well-known ability of agonists of Group I mGluRs to prevent neuronal apoptosis. Dr. Ye also discovered that PIKE is amplified in numerous human cancers and acts as a proto-oncogene by activating Akt in 2004. His lab established the nuclear signaling of NGF in promoting neuronal survival. In 2008, he discovered a novel asparagine proteinase (AEP) that mediates neuronal cell death during stroke, and PIKE robustly inhibits this protease activation, preventing neuronal damage in stroke. He also finds that PIKE binds netrin receptors UNC5B and DCC and exerts neuroprotective functions. In 2010, he identified numerous novel TrkA and TrkB agonists. These small molecules exhibit potent neurotrophic effect and display great therapeutic potentials for various neurological diseases including AD. Now, one of the small TrkB agonists is in IND drug development stage for treating AD. Most recently, he has also discovered oral insulin mimetic compounds for treating diabetes. Most recently, he found that AEP acts as a novel delta-secretase that cleaves both APP and Tau and mediates AD pathogenesis. It is an innovative drug target for treating AD. His lab has identified the small molecular inhibitors that display promising therapeutic efficacy toward AD.

Research Interests: 1. The molecular mechanisms in Neurodegenerative diseases including Alzherimer’s disease and Parkinson’s diseases 2. Drug discovery and development for neurological diseases including depression, Parkinson’s disease and Alzheimer’s disease and human cancers 3. Neurotrophin signalings in neuronal survival and glioblastoma progression

Born in Jammu-Tawi, India. After receiving Bachelor’s degree in Pharmaceutical Technology from the Birla Institute of Technology, Pilani, India, Rameshwar K. Sharma in 1960 entered the University of Connecticut for graduate work in Medicinal Chemistry and received his Ph.D. in 1963. Subsequently, after several Post-doctoral positions, including at the Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts, he joined the University of Tennessee Medical Center at Memphis in 1970 where he rose to the rank of Full Tenured Professor of Biochemistry and Physiology. During this period through NIH Special Fellowship he spent two-years Sabbatical as a Visiting Professor at the McArdle Laboratory University of Wisconsin, Madison, in Dr. Henry Pitot’s lab, and subsequently additional two-years Sabbatical at the NIH, Bethesda in Dr. Michael Cashel’s lab. After Full Professorship at the Case Western University and Founder and Head of the Unit of Regulatory Biology at the Cleveland Clinic Foundation, Cleveland Ohio, he joined the University of Medicine and Dentistry at New Jersey as the Professor and Head of The Unit of Regulatory and Molecular Biology. Since July 2006 he is at the Salus University as a Distinguished Professor of Biochemistry and Molecular Biology. In a period spanning four decades, his research team has dedicated itself to the advancement of the field of membrane guanylate cyclase in the vertebrate systems. A few of its core findings that have impacted this and the field of cellular signal transduction follow. (1) With the discovery of the first membrane guanylate cyclase, ANF-RGC that was also the hormone receptor of ANF, the membrane guanylate cyclase surface receptor family was established. (2) It had a unique signal transduction mechanism. Instead of GTP in G-Protein signaling, it was regulated by ATP through its ARM module (ARM). The complete dissection of the module, followed through the concept-based analysis, localized a WTAPELL motif that controlled the entire signal transduction process, it was, then, predicted that this motif is the one that controls the ANF-RGC-dependent blood pressure in vasculature. This has now been proven true through the construction of the mouse genetic model. The mice lacking this motif are hypertensive. (3) The discovery and molecular characterization of the photoreceptor ROS-GC is a land mark event in the phototransduction field. It filled in the gap on the identity of the source of cyclic GMP that serves as a second messenger of the LIGHT signal; and made it possible to explain the principles of phototransduction in molecular and physiological terms. It also impacted the core membrane guanylate cyclase field by branching it into two: a transducer of both the hormone receptor and the intracellularly-generated Ca2+ signals. (4) ROS-GC field took additional direction when it was demonstrated that, besides phototransduction, it is biochemically linked with the transduction mechanisms of the inner segments of the retina, olfactory cilia and the olfactory bulb neurons. (5) The demonstration that ROS-GC is a Ca2+-bimodal switch, generated a new revolutionary concept where theoretically ROS-GC could be modulated through two different modes of Ca2+ signaling: via Ca2+-sensor GCAPS and S100B, the latter stimulating it and the mode found exclusively in cones and absent in rods. (6) Recently, an additional model of the photoreceptor ROS-GC1 has been disclosed. ROS-GC1 is responsive to the bicarbonate signal; it is not the pH effect, rather it binds to a specific motif of the ROS-GC and transduces the signal in generation of cyclic GMP. Preliminary findings suggest that this novel transduction system is present in a small number of mouse cones, and, importantly, is absent in the rods. This opens up a new area of sensory transduction mechanism, where it is meant to communicate with the external atmospheric carbon dioxide. The carbon dioxide is sensed through carbonic anhydrase, whose subtype has been detected in some cones, it converts CO2 to the bicarbonate, which, then, becomes the second messenger of CO2 and a signaling agent of ROS-GC1. Threaded through this past history and step-by-step gain in the field, This investigator feels fortunate that his group has made these important contributions in generating the field of membrane guanylate cyclase, establishing that cyclic GMP is an ubiquitous intracellular second messenger in prokaryotes and eukaryotes and that it plays a critical role in the control of physiological processes of cardiac vasculature, smooth muscle relaxation, blood volume, cellular growth, sensory transduction, neural plasticity, learning and memory. It is also gratifying to know that during this course he has been able to train and guide more than 35 doctoral and post-doctoral students, author 184 peer-reviewed research articles, including the editorship of three books, Special Editorship of two journals of Molecular and Cellular Biochemistry and the e-book editor of the Frontiers Molecular Neuroscience Research Topic, all focused on the field of membrane guanylate cyclases. At present I am on the editorial board of four international journals: Associate editor of the Frontiers in Molecular Neuroscience, Journal of Molecular and Cellular Biochemistry, Journal of Signal Transduction, Journal of Membrane Science & Technology. I am also the founding father and the President of the Guanylate Cyclase Innovative Biotechnology (www.gcibiotechnology.com).

Research Interest: Membrane guanylate cyclase in the vertebrate systems

George Perry (born April 12, 1953 in Lompoc, California) is a neuroscientist recognized in the field of Alzheimer's disease research particularly for his work on oxidative stress. Dr. Perry has studied at many universities and holds multiple degrees including a Bachelor of Arts degree in Zoology from the University of California Santa Barbara and a PhD in Marine Biology from the University of California at San Diego. He is distinguished as one of the top Alzheimer’s disease researchers with over 1000 publications, one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in free radical research. Dr. Perry is a Semmes Foundation Distinguished chair in Neurobiology and is an active participant in many other scientific associations. In addition, Perry is an Editor of numerous scientific journals including Journal of Alzheimer’s Disease which he founded in 1998. Today, Perry continues his love for research while working as Dean of the College of Sciences at The University of Texas at San Antonio.

Research Interests: 1) Neurodegeneration 2) Alzheimer’s Disease

Stephen D. Skaper received a PhD in biochemistry from the University of South Dakota and Laurea in chemistry from the University of Padua, Italy. He is currently Adjunct Professor in the Department of Pharmaceutical and Pharmacological Sciences (section on Pharmacology and Anesthesiology) at the University of Padua. From 1998-2008 he was a Senior Group Leader for Neurodegeneration Research, Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, United Kingdom. Prior to that he held academic research positions in the Department of Biology at the University of California, San Diego. Dr. Skaper has authored/co-authored over 300 research papers, book chapters and monographs, as well as having guest-edited six journal thematic issues and a volume of Methods in Molecular Biology on neurotrophic factors. He is Editor-in-Chief of CNS & Neurological Disorders Drug Targets, the Associate Editor of the American Journal of Neuroprotection and Neuroregeneration, and a Councillor of the International Association of Neurorestoratology. His research interests focus on the role of immune cells and their interactions in neuroinflammation, in particular with regards to neuropathic pain and autoimmune demyelinating diseases like multiple sclerosis, and the development of therapeutic strategies based on natural molecules. He is a member of Sigma I, Phi Lambda Upsilon, Alpha Chi Sigma, the Society for Neuroscience and the International Society of Cerebral Blood Flow and Metabolism

Track record of drug discovery project leadership experience: kinases, ion channels, G-protein-coupled receptors, DNA repair enzymes, growth factors, as well as close interactions with early phase units of the drug discovery process Genetics Research & Discovery Research) to identify and optimise tools for target validation studies, utilising RNAi, conditional and viral knockdown\outs\ins, transcriptomics, proteomics and in vitro cell-based disease or mechanism relevant assays in rodent systems

Aruna Sharma, MD is currently Secretary of Research at Uppsala University Hospital, Uppsala University, Sweden. She obtained her Bachelor of Science in 1971 and trained in Indian Medicine up to 1977 and engaged in medical research from 1978 to 1986 in India on hyperthermia induced brain dysfunction in the lab of Hari Sharma and Prasanta Kumar Dey under University Grants Commission and Indian Council of Medical Research Programs. She is a qualified experimental Neurpathologist and received her training at Karl Marx University Leipzig, Institute of Neurobiology (1987-1988); Semmelweis University Medical School, Department of Human Morphology and Developmental Biology, Budapest, Hungary (1988-1989), Free University Berlin, Germany (1989-1991) and Neuropathology Institute Uppsala (1992-1995). She was further engaged in experimental neuropathological research at Uppsala University Hospital in the laboratory of Neuropathology of Hari Sharma and Yngve Olsson under Swedish Medical Research Council Program. She continued to work with Hari Sharma and Jan Westman in the department of Neuroanatomy, Biomedical Centre, Uppsala University from 1996 until 2003 on neuroimmunohistochemistry of experimental and human brain diseases. Since 2004 she joined Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine and working with Hari Sharma on various research programs including Nanotechnology in the CNS and disease modulation by endocrine or cardiovascular anomalies in the CNS and neuroprotection under various National and International Research Programs. Dr Sharma is member of various Distinguished American Organizations and elected to receive the prestigious award “Women of the Years Representing Sweden Award 2009” for her outstanding contributions towards society by American Biographical Research Institute, USA; and “Best Professional Business Women Award 2010” For Setting Standard to Motivate, Excel and Inspire Others, Raleigh, North Carolina, USA. She has published over 50 original research papers in Reputed Neuroscience Journals and is currently Acquisition Editor of American Journal of Neuroproetction and Neuroregenartion.

Her main interest is now focused on Indian Medicinal drugs and their effects on the Central Nervous System Function, toxicology, neurorepair and neuroprotection. She is also investigating neurotoxicological profiles of many Ayurvedic traditional drugs with special reference to those containing metal oxide or metal ashes.

Jean-Pierre Mothet have been investigated the functions of astrocyte-neuron interactions and the novel brain messenger D-serine in synapse physiology in the central nervous system. He has 20 years of research experience with synaptic transmission and cell signalling. He received his MSc in Physiology at the University of Lyon in 1992 and then his PhD in Neuroscience from the University Pierre and Marie Curie, Paris, in 1996. During his PhD under the supervision of DR. Ladislav Tauc in Gif-sur-Yvette (France), he studied biophysics and neuropharmacology of synaptic transmission in the sea slug Aplysia. After his Ph.D, he moved to the USA to carry out postdoctoral research in the laboratory of Pr Solomon H. Snyder at The Johns Hopkins School of Medicine in Baltimore (USA). There he worked at exploring the functions and the synthesis pathway of brain D-amino acids a novel class of brain molecules with a special focus on D-serine. He discovered that D-serine rather than glycine is the endogenous coagonist of synaptic N-Methyl D-Aspartate subtype of glutamatergic receptors in the hippocampus, a breakthrough with profound lasting impact in the fields of synaptic physiology and neuropharmacology. He also helped to identify serine racemase the enzyme that synthesizes D-serine from L-serine in the brain. In 1999, he took a second postdoctoral position in the laboratory of Professor Jacopo Meldolesi In 1999 (Milano, Italy), one of the most eminent cell biologists in Europe where he got trained in the study of calcium-dependent exocytosis of transmitter release and membrane trafficking. Since 2000 as a CNRS scientist, he has been continuously developping an unique and very innovative project in France and EU on the neurobiology of D-serine. His team investigates the regulation of NMDA receptors by their co-agonists (D-serine and glycine) at synapses and circuits underlying memory formation, motivation and decision-making in the context of neuron-glia interactions of the healthy and diseased nervous system. He also explores the molecular and cellular events driving gliotransmission, i.e. the process by which glia releases chemical messengers, and the functional relevance of this process for synapses patterning and neuronal network functions. He was first to establish that astrocytes release D-serine through a calcium and SNARE protein-regulated exocytosis (PNAS 2005) of synaptobrevin2 positive secretory organelles (Glia 2008). More recently, he developed unique protocols for the purification of glial vesicles and found functional evidence for the existence of a vesicular transporter for D-serine (J Neurosci 2013). Growing on his expertise in the field, he has shown that in the hypothalamus D-serine released by astrocytes controls the direction and the amplitude of long-term synaptic plasticity (Cell 2006). Furthermore, his team has demonstrated that at mature synapses D-serine is the right co-agonist for synaptic GluN2A-containing NMDARs at glutamatergic neurons in the prefrontal cortex (Cereb Cortex 2012) and in the hippocampus (Cell 2012) while glycine is the co-agonist for extrasynaptic GluN2B-containing NMDARs. He has also shown that the identity of the co-agonist is synapse specific and developmentally regulated in the hippocampus paralleling the developmental switch of GluN2A/2B subunits (PNAS 2015). His team has also discovered that D-serine plays a central role in learning and memory and that a deficit in its synthesis is responsible for the cognitive and synaptic deficits associated to normal aging (Aging Cell 2006, 2012). He is currently leading the lab \'Gliotransmission and Synaptopathies\' at the Centre de Recherches en Neurobiologie et Neurophysiologie de Marseille (France) where his team is combining cell biology, biochemistry, and cellular electrophysiology with live cell imaging and the development of biosensors. In 2012, he was elected President of the French Club of Glial Cells an association aimed to ^romote and support research on glial cells. He is the member of the Editorial board of Frontiers in Synaptic Neuroscience and of PlosONE. His research is internationally recognized and has stimulated many research programs in academy and Industry in France and worldwide. His research have paved the ways for the development of new drug-based therapies of cognitive deficits during normal aging but also for those associated to psychiatric disorders such as schizophrenia.

Research Interests: 1. Regulation of NMDA receptors by their co-agonists in the healthy and diseased nervous system 2. Molecular and cellular mechanisms of gliotransmission and the functional impact of this process in synapse and neuronal network patterning and dynamics, 3. Development of technologies like biosensors.

Graduated in Biological Sciences (D.Sc.) and in Medicine and Surgery (M.D.) - Associate Professor of Pharmacology at University of Pavia -Teaching Pharmacology for students in Biological Sciences and in Chemistry - Visiting: (1) Department of Neurology and (2) Cerebral Metabolism Research Laboratory, University of Lund, Sweden; (3) Department of Psychobiology, University of California ICI, U.S.A.; (4) Max Plank Institute for Neurochemistry, University of Gottingen, Germany; (5) San Diego Alzheimer’s Disease Research Center, University of California, San Diego, U.S.A.. Research activities: biochemical studies (Functional Proteomics and Metabolomics) on Physiopathology and Pharmacology of the Central Nervous System in experimental conditions of hypoxia, ischaemia, hyperammoniaemia, ipoglycaemia on the cerebral energy metabolism and actions of drugs on the brain energy state; molecular mechanisms of ageing and drugs' interference; the study of Parkinson’s disease and drugs' actions in Dementia; clinical studies on Molecular Medicine and Human Genetics on patients affected by neurological diseases (Dementia) or Alzheimer’s disease. Scientific research activity: 349 total papers: no. 129 on peer international reviews (IF about 350, only ISI publications); no. 66 Congress Proceedings and Acts; no. 154 communications in International Meetings, participating to no. 219 scientific Congress; officially invited to no. 214 Congress since 1993; from 2010 no. 56 as speaker; 9 Member of Organizing Committee or Session Chair/Co-Chair. International appointments as: (A) International ad hoc Reviewer for: - Research Founding Grants (Neuroscience) of The Wellcome Trust Foundation, London, United Kingdom (since 1994) - British Medical Council (asked 2014) inserted as - Reviewer’s Database for Founding of United Kingdom SBS, North Star House, Swinodon, U.K. - Listed as International Expert for the evaluation of Research Grant Programs of the European Commission Research Directorate General, Life Sciences: Health Research, European Union, Brussels. - Reviewer’s Database of Journal of Neuroscience - Reviewer’s Database of European Journal of Neurology And Committee Member of Italian Ministry for Scientific Research Grants (MIUR). (B) Member of the International Experts Panel of the Medical Science Monitor (since 2003), Albertson, New York, U.S.A. (C) Participant to ex Internship Program for U.S.A. students of New York Academy of Science, New York, U.S.A. Accredited Researcher for grants at National Institute of Health (NIH - U.S.A.). (D) Medical Credits at San Diego Alzheimer’s Disease Research Center Conference of University of California, San Diego, U.S.A. (E) Member of the Editorial Boards of: - Member of the Science Advisory Board – Arlington, U.S.A.. - Member of the Editorial Board of “Neurological Disorders & Therapy” – U.S.A. - VIP Member of EB of Neural Regeneration Research, Supervisor Ministry of Health - China (until 2013). - Member of EB of Journal of Neurological Disorders - Member of EB of “Aging and Neurodegeneration” – Anhui Medical University, China - Academic Editor of International Neuropsychiatric Disease Journal. - Member of EB of Journal of Depression and Anxiety – Los Angeles, California, U.S.A.. - Member of EB of International Journal of Emergency Mental Health and Human Resilience – Foster City, California, U.S.A.. - Member of EB of International Journal of Neurology Research – Sheung Wan, Hong Kong (China) - Member of EB of Journal of Neurology and Neuroscience – Wilmington City, Delaware, U.S.A.. (N) ad hoc Reviewer for over of 25 Journals: (in 1989) for Circulation Research; reviewer (from 1989) for Mechanisms of Ageing and Development; reviewer (in 2003) for Molecular Brain Research; reviewer (in 2004) of the Cochrane Dementia and Cognitive Improvement Group, Department of Clinical Gerontology, Oxford, U.K.; reviewer (since 2004) for Experimental Gerontology; reviewer (in 2004) for the “Bioastronautics Critical Path Roadmap Document”, Bioastronautics Research Division of NASA, U.S.A.; reviewer (since 2004) of The Journal of Clinical Pharmacology; reviewer (from 2011) of Complementary Medicine and Drug Discovery; reviewer (in 2011) for Drugs Today, Prous Thomson Reuters; reviewer (in 2011) for Neuropharmacology, Vascular Pharmacology, Journal of Neurological Disorder; reviewer (in 2012) for Vascular BMC Neurology; reviewer (in 2013) for Journal Neuroscience Research, Free Radical Research, Pharmacological Reports, PLOS ONE, Journal of Cytology & Histology, Neurological Research; reviewer (from 2014) for Neurochemical Research, Neural Regeneration Research, Journal Neurological Disorders (4 times), Molecular Neurobiology, Journal Proteome Research (3 times), Neuroscience Letters (3 times), Recent Patents on CNS Drug Discovery (Bentham Science Eds), Neuroscience Research, British Medical Journal, Metabolic Brain Disease.

Research Interests: Biochemical studies (Functional Proteomics and Metabolomics) on Physiopathology and Pharmacology of the Central Nervous System in experimental conditions of hypoxia, ischaemia, hyperammoniaemia, ipoglycaemia on the cerebral energy metabolism and actions of drugs on the brain energy state; molecular mechanisms of ageing and drugs' interference; the study of Parkinson’s disease and drugs' actions in Dementia; clinical studies on Molecular Medicine and Human Genetics on patients affected by neurological diseases (Dementia) or Alzheimer’s disease.